/BTAI
BTAI Stock - BioXcel Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.73-5.46%
$0.10 (-5.46%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1206.4%upside
Target: $22.60
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BTAI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.71 – $1.75
TARGET (TP)$22.60
STOP LOSS$1.59
RISK/REWARD1:149.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.21
52W High$9.26
52W Low$1.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.27M | $1.38M | $375,000 | N/A | N/A |
| Gross Profit | $123,000 | $120,000 | $355,000 | $-297,000 | N/A |
| Gross Margin | 5.4% | 8.7% | 94.7% | N/A | N/A |
| Operating Income | $-67,245,000 | $-171,782,000 | $-159,645,000 | $-105,895,000 | $-82,297,000 |
| Net Income | $-59,599,000 | $-179,053,000 | $-165,757,000 | $-106,931,000 | $-82,169,000 |
| Net Margin | -2630.1% | -12974.9% | -44201.9% | N/A | N/A |
| EPS | $-23.51 | $-98.35 | $-94.67 | $-64.87 | $-60.63 |
Company Overview
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
17%
Hold / Neutral
5
83%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish5 Neutral/Bearish
Price Targets
$13
Average Target
↑ 651.4% Upside
Now
$4
Low
$13
Average
$22
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 21st 2024 | UBS | Downgrade | Neutral | $4← $9 |
| August 15th 2023 | Mizuho | Downgrade | Neutral | $4← $40 |
| July 17th 2023 | Guggenheim | Downgrade | Neutral | - |
| March 10th 2023 | Jefferies | Downgrade | Hold | $22← $20 |
| December 1st 2022 | Goldman | Upgrade | Neutral | $16 |
| July 7th 2022 | Mizuho | Initiation | Buy | $19 |
Earnings History & Surprises
BTAIBeat Rate
42%
Last 19 quarters
Avg Surprise
+0.8%
EPS vs Estimate
Beats / Misses
8/11
Last 12 quarters
Latest EPS
$-2.18
Q4 2025
EPS Surprise History
Q1 24
+22.4%
$-12.16vs$-15.68
Q2 24
-27.9%
$-13.92vs$-10.88
Q3 24
+72.4%
$-3.36vs$-12.16
Q4 24
+36.0%
$-5.12vs$-8.00
Q1 25
+18.1%
$-3.57vs$-4.36
Q2 25
+44.9%
$-1.50vs$-2.72
Q3 25
-6.5%
$-2.45vs$-2.30
Q4 25
-41.6%
$-2.18vs$-1.54
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.82 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-1.54 | $-2.18 | -41.6% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-2.30 | $-2.45 | -6.5% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-2.72 | $-1.50 | +44.9% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-4.36 | $-3.57 | +18.1% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-8.00 | $-5.12 | +36.0% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-12.16 | $-3.36 | +72.4% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-10.88 | $-13.92 | -27.9% | ✗ MISS |
Q1 2024 | Mar 12, 2024 | $-15.68 | $-12.16 | +22.4% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-20.64 | $-27.52 | -33.3% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-27.52 | $-29.28 | -6.4% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-24.96 | $-29.44 | -17.9% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-23.84 | $-31.20 | -30.9% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-21.44 | $-23.84 | -11.2% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-19.20 | $-21.60 | -12.5% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-19.36 | $-17.92 | +7.4% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-18.88 | $-14.88 | +21.2% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-17.28 | $-15.36 | +11.1% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-16.48 | $-17.76 | -7.8% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-14.24 | $-17.28 | -21.3% | ✗ MISS |
Latest News
BioXcel Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 12, 2025, 04:43 PM
BioXcel Therapeutics Q3 EPS $(2.18) Misses $(1.13) Estimate, Sales $98.000K Miss $212.500K Estimate
📉 NegativeBenzinga•Nov 12, 2025, 12:14 PM
Bioxcel Therapeutics Announced Results From The Correlation Study Related To Exploratory Efficacy Outcomes From SERENITY At-home Trial. The Results, Along With The Data From The Serenity At-home Trial, Will Be Included In The Supplemental New Drug Application Submission Planned For 1Q26
➖ NeutralBenzinga•Oct 14, 2025, 11:07 AM
BioXcel Therapeutics Announces Compliance With Nasdaq MVLS Rule Following September 17 Notice From Listing Qualifications Department
➖ NeutralBenzinga•Sep 18, 2025, 11:02 AM
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target
📈 PositiveBenzinga•Sep 15, 2025, 12:03 PM
Mizuho Maintains Neutral on BioXcel Therapeutics, Raises Price Target to $4
➖ NeutralBenzinga•Sep 12, 2025, 11:57 AM
Bioxcel Therapeutics Announced Topline Exploratory Efficacy Data From SERENITY At-home Pivotal Phase 3 Safety Trial, Which Demonstrated Bxcl501 Had Continued Effects And Consistent Benefit With Repeat Dosing For Agitation Associated With Bipolar Disorders Or Schizophrenia
📈 PositiveBenzinga•Sep 10, 2025, 10:31 AM
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target
📈 PositiveBenzinga•Aug 28, 2025, 11:11 AM
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Aug 27, 2025, 11:25 AM
BioXcel Therapeutics Shares To Resume Trading At 7:30AM ET
➖ NeutralBenzinga•Aug 27, 2025, 11:22 AM
BioXcel Eyes Q1 2026 sNDA For IGALMI At-Home Use Following BXCL501 Phase 3 trial Results
📈 PositiveBenzinga•Aug 27, 2025, 11:10 AM
BioXcel Therapeutics Says BXCL501 Meets Primary Endpoint In SERENITY At-Home Trial For Bipolar And Schizophrenia Agitation
📈 PositiveBenzinga•Aug 27, 2025, 11:06 AM
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 27, 2025, 10:55 AM
BioXcel Therapeutics shares are trading higher after the company announced it will reveal Phase 3 data for its at-home agitation treatment of BXCL501.
📈 PositiveBenzinga•Aug 26, 2025, 08:15 PM
BioXcel To Reveal Phase 3 Data For At-Home Agitation Treatment BXCL501 In Investor Call On August 27
➖ NeutralBenzinga•Aug 26, 2025, 08:08 PM
BioXcel Reaches Key Milestone in Phase 3 Trial for At-Home Agitation Treatment, Results Coming in August
📈 PositiveBenzinga•Aug 19, 2025, 11:06 AM
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target
📈 PositiveBenzinga•Aug 19, 2025, 10:53 AM
BioXcel Therapeutics shares are trading higher after the company announced it has achieved alignment with the FDA on its sNDA package to expand IGALMI.
📈 PositiveBenzinga•Aug 18, 2025, 03:11 PM
Market-Moving News for August 18th
➖ NeutralBenzinga•Aug 18, 2025, 11:45 AM•Also: ,
BioXcel Therapeutics Achieves Alignment With FDA On sNDA Package To Expand IGALMI Label For At-Home Outpatient Treatment Of Agitation In Bipolar Disorders Or Schizophrenia
📈 PositiveBenzinga•Aug 18, 2025, 11:04 AM
Frequently Asked Questions about BTAI
What is BTAI's current stock price?
BioXcel Therapeutics, Inc. (BTAI) is currently trading at $1.73 per share. The stock has moved -5.46% today.
What is the analyst price target for BTAI?
The average analyst price target for BTAI is $22.60, based on 1 analyst.
What sector is BioXcel Therapeutics, Inc. in?
BioXcel Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BTAI's market cap?
BioXcel Therapeutics, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does BTAI pay dividends?
No, BioXcel Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
EVAX
Evaxion Biotech A/S
$4.70
Mkt Cap: $0.0B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
MAIA
MAIA Biotechnology, Inc.
$1.22
Mkt Cap: $0.0B
MURA
Mural Oncology plc
$2.04
Mkt Cap: $0.0B
PYPD
PolyPid Ltd.
$3.97
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
VERU
Veru Inc.
$2.32
Mkt Cap: $0.0B
Explore stocks similar to BTAI for comparison